ALK and non-small cell lung carcinoma: Albeit this study has some limitations due to the unbalance between Asian patients treated with the different TKIs (a fact that favors alectinib’s greater numbers and may have over-estimated its efficacy in this population), it still represents a useful addition to our knowledge of these drugs activity in ALK-translocated NSCLC patients.